Get the Stockscreener App
34.30
1.30%
0.44
Pre-market:
34.99
0.69
+2.01%
Moderna Inc stock is traded at $34.30, with a volume of 7.43M.
It is up +1.30% in the last 24 hours and up +21.46% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$33.86
Open:
$34.298
24h Volume:
7.43M
Relative Volume:
0.70
Market Cap:
$13.40B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.929
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+11.15%
1M Performance:
+21.46%
6M Performance:
+4.61%
1Y Performance:
-20.55%
1-Day Range:
$33.94
$35.41
1-Week Range:
$31.27
$37.10
52-Week Range:
$22.28
$45.40
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
34.30 | 13.23B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna reiterates target of up to 10% revenue growth in 2026 (MRNA:NASDAQ) - Seeking Alpha
Moderna expects sales near upper end of 2025 forecast - Business Day
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - Milwaukee Journal Sentinel
Moderna expects $1.9 billion revenue for 2025, exceeds cost targets By Investing.com - Investing.com India
Moderna expects full-year 2025 revenue of $1.9B - breakingthenews.net
Moderna climbs on $1.9 billion 2025 sales forecast - TradingView — Track All Markets
Moderna stock rises as revenue outlook exceeds estimates By Investing.com - Investing.com Canada
Moderna Sees Sales Boost From Better-Than-Expected Covid Shots - Bloomberg.com
Moderna expects $1.9 billion in sales, trims costs forecast for 2025 - Reuters
Moderna raises 2025 revenue forecast to $1.9 billion - StreetInsider
Moderna chair warns of ‘dystopia’ amid US science pullback - Semafor
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - St. Cloud Times
The mRNA Rivalry in 2026: A Tale of Financial Fortress Versus Speculative Despair - AD HOC NEWS
Moderna Vaccine (Spikevax) Review: Why This COVID-19 Shot Still Matters in 2026 - AD HOC NEWS
SG Americas Securities LLC Has $7.46 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates - Lincoln Courier
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics - FinancialContent
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why - sharewise.com
Moderna (MRNA) Is Up 14.8% After Filing Global Applications For Its mRNA Flu Vaccine mRNA-1010 - Yahoo Finance
Biotech Co. Says HHS Infringed Patent With Moderna Vax Deal - Law360
What Analysts Are Saying About Moderna Stock - Benzinga
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge - FinancialContent
UBS Lowers Moderna (MRNA) Price Target to $34, Rating Changed to Neutral | MRNA Stock News - GuruFocus
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonald's, Moderna, and More - 24/7 Wall St.
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Moderna (MRNA) - The Globe and Mail
Bayer sues COVID vaccine makers over mRNA technology - ET Pharma
My Top 5 Stocks to Buy in Early 2026 - The Motley Fool
Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - The Asheville Citizen Times
Bayer Sues Biontech and Pfizer Over Patents for Covid Vaccines - MarketScreener
Bayer Targets Pfizer, Moderna, J&J For Covid Jab Royalties - Law360
Moderna, Inc. (MRNA) Issues Shareholder Letter Highlighting Stra - GuruFocus
Bayer Seeks Covid-Vaccine Royalties Over Crop-Technology Patent - Bloomberg Law News
UBS Downgrades Moderna (MRNA) Amid Revenue Concerns - GuruFocus
Moderna downgraded to neutral at UBS on questions over revenue growth - MSN
Moderna (NASDAQ:MRNA) Stock Price Up 8.6%Time to Buy? - MarketBeat
Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus - TechStock²
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine - The Globe and Mail
Moderna jumps 10% as BofA hikes target price - breakingthenews.net
Moderna rallies after BofA raises its price target to $24 from $21 - Sherwood News
BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating - MarketScreener
Moderna stock price target raised to $24 from $21 at BofA Securities - Investing.com UK
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine - Bartlesville Examiner-Enterprise
Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches - Proactive financial news
Key facts: Moderna announces 2025 achievements; mRNA-1010 shows efficacy - TradingView — Track All Markets
CDC updates childhood vaccine schedule (PFE:NYSE) - Seeking Alpha
Jefferies reiterates Hold rating on Moderna stock, maintains $30 price target - Investing.com UK
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):